# What This Bill Does

This bill extends a financial incentive program for Medicare that encourages the use of biosimilar drugs—which are cheaper, biologically-based alternatives to expensive brand-name medications. Right now, Medicare has a special payment boost for doctors and hospitals that use these lower-cost biosimilars instead of the pricier original drugs. The bill simply pushes back the expiration date of this incentive program from 2027 to 2032, giving the program five extra years to operate.

# Who This Affects and Why It Matters

If you're on Medicare, this could mean continued access to more affordable drug options. Biosimilars are copies of complex biological drugs used to treat conditions like rheumatoid arthritis, certain cancers, and autoimmune diseases. They work essentially the same way as the originals but cost significantly less. By extending the payment incentive, the bill encourages doctors and hospitals to keep prescribing these cheaper alternatives rather than switching back to expensive brand-name versions once the original deadline hits. This helps keep Medicare costs down, which can mean lower premiums and out-of-pocket costs for seniors and people with disabilities.

The practical effect is straightforward: without this extension, the financial reward for using biosimilars would disappear in 2027, potentially making doctors less likely to recommend them. By extending it to 2032, the bill maintains that encouragement for five more years, helping ensure that patients continue to have access to these cost-saving medications and that Medicare's budget doesn't get strained by unnecessary spending on expensive brand-name drugs when equally effective biosimilars are available.

To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.